The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.

Shenyang Xingqi Pharmaceutical's strong financials and high ROE hint at potential long-term stock value increase. Impressive net income growth and efficient earnings reinvestment suggest a positive outlook.

Despite Shenyang Xingqi Pharmaceutical Ltd's weak recent revenue performance, the high P/S ratio points to investors holding stocks, anticipating significant revenue recovery. But with forecasted growth mirrored by the industry, the current ratio may not be sustainable without improved performance.

Despite Shenyang Xingqi's lackluster revenue growth, the high P/S ratio implies investors are holding stocks in anticipation of a major revenue rebound. Yet, the expected revenue growth that matches with the industry's might not uphold this high P/S in the long run. An uplift in performance is necessary to justify this current ratio.

Shenyang Xingqi PharmaceuticalLtd's performance appears to be quite favorable, particularly due to high reinvestment of its profits leading to substantial earnings growth. Analysts are expecting the company to continue its recent growth streak.